Mineralys Therapeutics, Inc.MLYSNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank20
3Y CAGR-18.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-18.9%/yr
Annual compound
Percentile
P20
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 62.01% |
| 2024 | 66.63% |
| 2023 | 173.40% |
| 2022 | 116.34% |
| 2021 | 354.32% |
| 2020 | 0.00% |